Aytu BioPharma, Inc.
看多

AYTU

With an upcoming EPS to be released on the 19th, I believe this will act as a catalyst and send the trend lines at an even steeper incline. Their quarterly revenue growth for Q2 of fiscal 2019 year they gained an impressive 71%. I highly suggest everyone purchase and hold until the end of the month.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。